Evidence map›Paper›PMID 40873681›Full record

ReviewInternational journal of nanomedicine2025

Application of Metal-Organic Frameworks Nanoparticles in the Diagnosis and Treatment of Breast Cancer.

Xin-Ran Jiang, Jiahao Mi, Yiling Wang, Mengqi Yin, Yuna Tong, Yuxuan Zhu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xin-Ran Jiang *Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, People's Republic of China.
Jiahao Mi *Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, People's Republic of China.
Yiling WangDepartment of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, People's Republic of China.
Mengqi YinDepartment of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, People's Republic of China.
Yuna TongDepartment of Nephrology, The Third People's Hospital of Chengdu, Chengdu, 610031, People's Republic of China.
Yuxuan ZhuDepartment of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, People's Republic of China.ORCID 0000-0002-5234-8506

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer remains the most prevalent malignancy among women and the second leading cause of cancer-related mortality worldwide, primarily attributable to delayed diagnosis and limited therapeutic efficacy. Recent nanotechnology advances exhibit transformative potential in breast cancer management. Metal-organic frameworks (MOFs) have emerged as promising nanoplatforms for biomedical applications due to their exceptional adsorption capacity, high surface area, tunable porosity, structural stability, and facile surface functionalization-properties enabling advanced drug delivery systems (DDSs). This review systematically summarizes MOFs for DDSs and their applications in breast cancer. Classification by metal-ligand composition precedes critical analysis of synthesis methodologies, including comparative advantages and limitations alongside key factors influencing biomedical performance. A dedicated sections highlights normal and stimuli-responsive MOFs activated by endogenous or exogenous triggers. Furthermore, the application of multifunctional MOFs has been comprehensively explored, including chemotherapy, photothermal therapy, photodynamic therapy, immunotherapy, and diagnostic-therapeutic integration in breast cancer. Finally, challenges and possible solutions for MOFs in drug delivery are discussed.

Indexed as

Breast NeoplasmsMetal-Organic FrameworksNanoparticlesAnimalsAntineoplastic AgentsDrug Delivery SystemsFemaleHumansImmunotherapyPhotochemotherapyAntineoplastic AgentsMetal-Organic Frameworksbreast cancerdrug delivery systemsmetal-organic frameworks

Identifiers

PMID40873681
PMCPMC12379968

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.